Conversely, pirfenidone, another antifibrotic compound with therapeutic efficacy in ILD, was found to aggravate vascular remodeling in Fra-2 transgenic mice by inducing a strong downregulation of VE-cadherin in lung ECs [90]. Here, FOSL2 is linked to interstitial lung disease.